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Abstract
Background: Consistently reported prognostic factors for glioblastoma (GBM) are age, extent of surgery, performance
status, IDH1 mutational status, and MGMT promoter methylation status. We aimed to integrate biological and clinical
prognostic factors into a nomogram intended to predict the survival time of an individual GBM patient treated with a
standard regimen. In a previous study we showed that the methylation status of the DGKI promoter identified patients with
MGMT-methylated tumors that responded poorly to the standard regimen. We further evaluated the potential prognostic
value of DGKI methylation status.
Methods: 399 patients with newly diagnosed GBM and treated with a standard regimen were retrospectively included in
this study. Survival modelling was performed on two patient populations: intention-to-treat population of all included
patients (population 1) and MGMT-methylated patients (population 2). Cox proportional hazard models were fitted to
identify the main prognostic factors. A nomogram was developed for population 1. The prognostic value of DGKI promoter
methylation status was evaluated on population 1 and population 2.
Results: The nomogram-based stratification of the cohort identified two risk groups (high/low) with significantly different
median survival. We validated the prognostic value of DGKI methylation status for MGMT-methylated patients. We also
demonstrated that the DGKI methylation status identified 22% of poorly responding patients in the low-risk group defined
by the nomogram.
Conclusions: Our results improve the conventional MGMT stratification of GBM patients receiving standard treatment. These
results could help the interpretation of published or ongoing clinical trial outcomes and refine patient recruitment in the
future.
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Introduction
Glioblastoma (GBM) is the most common and aggressive
primary brain tumor in adults. Its prognosis remains extremely
poor, despite multimodal treatment by surgery, radiotherapy, and
temozolomide-based chemotherapy (standard regimen) [1]. The
most consistently reported clinical prognostic factors for GBM are
age, extent of surgery, and performance status [2,3,4]. The
somatic mutation affecting amino acid 132 in the isocitrate
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dehydrogenases 1 gene (IDH1) is also associated with a better
clinical outcome in gliomas, including glioblastoma. However, this
mutation is rare in primary GBMs (approximately 6%) [5,6,7].
The methylation status of the O6-methylguanine DNA methyl-
transferase gene (MGMT) promoter is currently the strongest
predictive biomarker of outcome and benefit from temozolomide-
based treatment of GBM [8]. In 2008, Gorlia et al. integrated
biological and clinical prognostic factors and their independent
and combined predictive powers into nomograms for GBM
patients treated with the standard regimen [9]. These nomograms
can be used to predict an individual patient’s median survival and
the probability of survival at two years. These nomograms can be
of interest in patient counselling and in the design and
interpretation of clinical trials. However, the authors stressed a
lack of statistical power in their subgroup analysis of patients who
had an available MGMT promoter methylation status (n = 103).
In this study, we retrospectively analysed 399 GBM patients
treated with the standard regimen (intention-to-treat). We
identified the main clinical prognostic factors in this cohort and
compared our results with those of the EORTC (European
Organisation for Research and Treatment of Cancer) and NCIC
(National Cancer Institute of Canada) trial 26981-22981/CE.3.
We propose an updated nomogram intended to predict the
survival time of an individual GBM patient. In a previous study on
50 GBM patients treated with the standard regimen, we showed
that the methylation status of the diacylglycerol kinase iota gene
(DGKI) promoter identified patients with MGMT-methylated
tumors that responded poorly to the standard regimen [10]. The
role of DGKI and the functional consequences of its methylation
status have never been investigated in gliomas but DGKI regulates
Ras signalling, an oncogenic pathway frequently altered in GBM
[11,12]. We further evaluated the potential predictive value of
DGKI methylation status in the context of both MGMT-
methylated and intention-to-treat populations.
Materials and Methods
Patients and tissue samples
This multi-center retrospective cohort included 399 patients
treated in the Departments of Neurosurgery/Neuro-oncology of
Angers (n = 28), Marseille (n = 52), Paris-Salpeˆtrie`re (n = 227),
Rennes (n = 50), and Poitiers (n = 42) between 2006 and 2011. The
inclusion criteria were as follows: 1) patients aged 18 years or
more, 2) diagnosis of a primary GBM (WHO grade IV), 3) detailed
clinical information at diagnosis and during follow-up, 4)
treatment with radiotherapy and concurrent/adjuvant temozolo-
mide (standard regimen), and 5) availability of tumor tissue with
informed consent in accordance with French regulations and the
Helsinki Declaration. All patients included in this study fulfilled
the inclusion criteria. Particularly, all patients received a radio-
chemotherapy regimen in accordance with the standard of care.
Follow-up for included patients ranged from 24 days to 5.2 years
(median, 15.5 months). Tumor samples were snap-frozen imme-
diately after resection and stored in tumor banks under the
following authorization numbers: (Centre de Ressources Biologi-
ques, DC-2011-1467, Angers), 2008/70 (AP-HM Tumor Bank,
Marseille), DC 2009-957 (OncoNeuroTheque Salpeˆtrie`re, Paris),
DHOS/2004/04056 (Hospital Tumor Bank, Poitiers), and AC-
2010-77 (Centre de Ressources Biologiques, Rennes). The extent
of surgery was evaluated with an enhanced magnetic resonance
imaging (MRI) performed within 24 hours after the resection. All
samples presented at least 70% of tumor cells. For each tumor
sample, DNA was extracted using the NucleoSpin Tissue Kit
(Macherey Nagel) according to the manufacturer’s instructions.
The quality of the DNA samples was assessed by electrophoresis
on a 1% agarose gel. Only high quality genomic DNAs were
selected for further analyses.
Two patient populations were considered in this study: the
population of all included patients (population 1) and the subgroup
of MGMT-methylated patients (population 2). Population 1 was
used to identify the main clinical prognostic factors and to
compare our results with those of the EORTC and NCIC trial
26981-22981/CE.3 [9]. Population 2 was studied to evaluate the
strength and importance of these prognostic factors after
conventional MGMT stratification. The effect of DGKI promoter
methylation status on the prognosis of GBM patients assigned to
standard treatment was also evaluated in MGMT-methylated
patients. Patients from population 2 were randomly assigned to a
training cohort and a validation cohort of equal sizes in a
randomized block design stratified by the hospital center. Table 1
shows the demographic and clinical characteristics of the patients
included in this study.
IDH1 mutation
Tumor DNA was screened for somatic mutations in IDH1
codon 132 via exon 4 PCR amplification and direct sequencing as
previously described [13]. Because IDH1 mutation is sufficient to
establish the ‘‘glioma-CpG island methylator phenotype’’ (G-
CIMP), we did not take this phenotype into account in our analysis
[14].
DNA methylation analysis
DNA was bisulfite-modified using the EZ DNA Methylation Kit
(Zymo Research). The methylation percentage (%met) of the
MGMT promoter was measured using the PyroMark Q96 CpG
MGMT kit (Qiagen) (average percentage of the five tested CpG
sites). The DGKI promoter’s %met was measured using VeraCode
GoldenGate Methylation technology (Illumina Inc.) or by
pyrosequencing. PCR and pyrosequencing primers were designed
using the Pyrosequencing Assay Design Software (Qiagen). The
primers and PCR conditions are given in Figure S1. The
reproducibility of the pyrosequencing assays was assessed on a
subset of 21 patients for MGMT (Pearson correlation coefficient
r = 0.999, p,1e-08) and of 26 patients for DGKI (Pearson
correlation coefficient r = 0.994, p,1e-08). The consistency
between VeraCode GoldenGate Methylation technology and
pyrosequencing was assessed on 24 patients for DGKI (Pearson
correlation coefficient r = 0.89, p,1e-08). The assessment of
MGMT and DGKI %met was conducted at the Rennes hospital.
For MGMT, we used the 8% methylation threshold defined on an
independent data set by Quillien et al. [15]. The DGKI
methylation threshold of 28% was determined in the training
cohort using the risksetROC R package (AUC = 0.61).
Statistical analyses
Overall survival (OS) and progression-free survival (PFS) were
estimated using the Kaplan-Meier method. Comparisons between
survival groups were performed using a log-rank test for binary
variables, and a log-rank trend test for ordered categories. Cox
proportional hazard models provided estimates of the hazard
ratios (HRs). From these tests, variables with p-values less than 5%
were candidates for the multivariate analyses. In population 1, the
Cox proportional hazards model was then used with forward
stepwise model selection. We have checked that no evidence of
violation of the proportional hazards assumption was found. The
probability of inclusion of a factor in the multivariate model was
estimated by using the bootstrap resampling technique as
Methylation of DGKI Improves Stratification in GBM
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described in Gorlia et al. [9]. All tests were adjusted for hospital
center. Analyses were carried out using the survival R package.
A nomogram was developed for population 1 to predict each
patient’s median survival and probability of survival at two years,
taking into account their clinical characteristics. Variables with a
probability of inclusion higher than 90% based on 1000 bootstrap
samples were included in the final model. The definition of two
risk groups (high/low) was based on the value of the linear
predictor underlying the nomogram; values greater than or equal
to zero were assigned to the high-risk group, and negative values
were assigned to the low-risk group (the total points cut-off
between high and low-risk is the value matching a linear predictor
value equal to zero). The accuracy of predictions was assessed by
estimating the model’s calibration and discrimination measured by
the Concordance index corrected for optimism (C-index). The
nomogram was built using the rms R package.
Table 1. Patients demographic and clinical characteristics.
Characteristics
Population 1
(n =399)
EORTC cohort*
(n =103)
Population 2 training
(n=86)
Population 2 validation
(n=89)
Age (years)
Median 59 57 59
Range 21–88 29–88 26–80
Age - no. (%)
#50 95 (24) 44 (43) 23 (27) 22 (25)
51–60 130 (33) 40 (39) 30 (35) 26 (29)
.60 174 (44) 19 (18) 33 (38) 41 (46)
Sex - no. (%)
Women 161 (40) 38 (37) 41 (48) 41 (46)
Men 238 (60) 65 (63) 45 (52) 48 (54)
KPS (%)
Median 80 80 80
Range 40–100 40–100 40–100
KPS - no. (%)
#70 37 (9) 10 (12) 10 (11)
.70 331 (83) 69 (80) 72 (81)
Missing 31 (8) 7 (8) 7 (8)
Extent of surgery - no. (%)
Biopsy 30 (8) 0 (0) 10 (12) 5 (6)
Partial resection 140 (35) 56 (54) 25 (29) 34 (38)
Complete resection 220 (55) 47 (46) 50 (58) 49 (55)
Missing 9 (2) 0 (0) 1 (1) 1 (1)
IDH1 mutational status - no. (%)
Mutated 18 (5) 5 (6) 8 (9)
Wild-type 364 (91) 80 (93) 77 (87)
Missing 17 (4) 1 (1) 4 (4)
MGMT methylation status - no. (%)
Methylated 175 (44) 45 (44) 86 (100) 89 (100)
Unmethylated 224 (56) 58 (56) 0 (0) 0 (0)
DGKI methylation status - no. (%)
Methylated 95 (24) 22 (26) 21 (24)
Ummethylated 304 (76) 61 (74) 68 (76)
Overall survival - mo
Median 19.1 29.6 30.2
95% CI 17.1–20.8 22.5–46.7 24.1–46.8
Progression-free survival - mo
Median 10.8 15.2 15.6
95% CI 10.1–11.9 13.8–19.1 13.1–23.4
*EORTC and NCIC trial 26981-22981/CE.3 population 3: GBM patients who underwent partial or complete resection and were assigned temozolomide and radiotherapy
in the presence of an MGMT promoter methylation assessment.
doi:10.1371/journal.pone.0104455.t001
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Results
Survival analysis of all included patients (population 1)
In population 1, univariate Cox analyses showed that age,
Karnofsky performance status (KPS), extent of surgery, IDH1
mutational status, MGMT promoter methylation status, and
DGKI promoter methylation status were significantly associated
with OS (Table 2). These variables remained significantly
associated with OS in the multivariate Cox analyses (Table 3).
The final multivariate Cox model used to build the nomogram
included age, KPS, extent of surgery, IDH1 mutational status, and
MGMT promoter methylation status. This model was associated
with a C-index corrected for optimism of 68%.
Figure 1A shows the nomogram for population 1. The total
number of points for each patient is obtained by summing the
points for each of the individual factors in the nomogram. The
median survival and probability of survival at two years for a given
patient are obtained by drawing a vertical line from the ‘‘total
points’’ axis down to the outcome axes. For example, a 55-year-old
patient with a KPS of 80 and a partly resected/IDH1 wild-type/
MGMT-methylated tumor has a total prognostic score of 129 and
is predicted to have a median survival of approximately 30 months
and a 60% probability of surviving two years. Because the cut-off
between high and low risk is 165 points, this patient is assigned to
the low-risk group. Patients in the low-risk group had a median OS
of 29.6 months (95% CI, 26.0–37.7), which was significantly
longer than 14.9 months (95% CI, 13.7–16.7) for patients in the
high-risk group (p,1e-08). A similar stratification was observed for
the PFS (Figure 1B).
Survival analysis of MGMT-methylated patients
(population 2)
In population 2, univariate Cox analyses showed that age, KPS,
and DGKI promoter methylation status were significantly
associated with OS in both the training and validation cohorts
(Table 2). In the multivariate Cox analyses, DGKI promoter
methylation status was the only variable with a probability of
inclusion higher than 90% in the training cohort. DGKI
methylation status stratified the MGMT-methylated patients into
two groups with significant differences in OS (19.9 months vs. 34.8
months, p = 0.008, 16.5 months vs. 37.8 months, p = 1e-4, training
and validation, respectively, figure 2A). The MGMT %met was
not significantly different (Student’s t-test) between the DGKI-
methylated and DGKI-unmethylated patients (p = 0.23).
The OS and PFS of the MGMT-methylated and DGKI-
methylated patients were not significantly different from the OS
and PFS of the MGMT-unmethylated patients (19.7 months vs.
14.9 months, 12.0 months vs. 9.0 months, OS and PFS,
respectively, Figure S2).
Prognostic value of DGKI methylation status in risk
groups (population 1)
The DGKI methylation status stratified the low-risk patients
into two groups with significant differences in OS and PFS (37.2
months vs. 19.9 months, 18.4 months vs. 12.5 months, OS and
PFS, respectively, figure 2B). The OS of low-risk and DGKI-
methylated patients was not significantly different from the OS of
high-risk patients (19.9 months vs. 14.9 months, p = 0.21). The
DGKI methylation status did not stratify the subgroup of high-risk
patients in the intention-to-treat population.
Table 3. Multivariate analyses of survival prognostic factors.
Population 1 (n =399)
HR (95% CI) p (%inclusion)
Age (years)
#50 .. 0.006 (92)
51–60 1.3 (1.1–1.6) ..
.60 .. ..
Karnofsky performance status (%)
#70 1.0 ,0.001 (99)
.70 0.4 (0.2–0.6) ..
Extent of surgery
Biopsy .. ,0.001 (98)
Partial resection 0.6 (0.5–0.8) ..
Complete resection .. ..
IDH1 mutational status
Mutated 1.0 0.02 (94)
Wild-type 4.1 (1.3–13.3) ..
MGMT methylation status
Methylated 1.0 ,0.001 (100)
Unmethylated 3.0 (2.2–4.2) ..
DGKI methylation status
Methylated 1.0 0.03 (74)
Unmethylated 0.7 (0.5–1.0) ..
NA = not available; N =not enough events to calculate upper 95% CI boundary; NS = not significant. For ordered categorical factors, the first value is the reference.
doi:10.1371/journal.pone.0104455.t003
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Discussion
We studied a retrospective cohort of 399 GBM patients
homogeneously treated with the standard regimen. The higher
OS at 6 and 12 months observed in our cohort in comparison to
the reference cohort of the EORTC trial [16] (Table S1) can be
explained by an improvement of surgical practices (55% of
complete resection in our cohort vs. 39% in EORTC trial),
continuation of standard treatment despite pseudoprogression,
and an earlier and/or easier access to bevacizumab treatment at
recurrence for patients progressing after 2007. This cohort was
used to identify the main clinical prognostic factors and to design a
nomogram intended to predict the survival time of an individual
patient. A nomogram-based stratification of the cohort identified
two risk groups (high/low) with significantly different median
survival. In the low-risk group, the DGKI promoter methylation
status identified poorly responding patients.
The prognostic factors identified in our study were age, KPS,
extent of surgery, IDH1 mutational status, and MGMT promoter
methylation status. This result is in agreement with the most
consistently reported prognostic factors for GBM [2,3,4,5,6,8].
From an individual patient’s perspective, a nomogram offers a
more tailored approach, taking into account their clinical
characteristics. This can be of interest in patient counselling and
in the design and interpretation of clinical trials. Therefore, we
propose a nomogram based on the prognostic factors identified in
our study. The nomogram can be used to predict an individual
patient’s median survival and probability of survival at two years.
The DGKI methylation status was not included in this nomogram
as it did not identify clinically relevant groups of patients in the
Figure 1. GBM patients assigned to standard treatment (population 1). (A) Nomogram for predicting median survival, probability of survival
at two years, and risk category. The total number of points for each patient is obtained by summing the points for each of the individual factors in the
nomogram. The median survival and probability of survival at two years for a given patient are obtained by drawing a vertical line from the ‘‘total
points’’ axis down to the outcome axes. The definition of two risk groups (high/low) is based on the value of the linear predictor underlying the
nomogram: values greater than or equal to zero were assigned to the high-risk group, and negative values were assigned to the low-risk group. The
total point value matching the null value of the linear predictor is 165. Example: a 55-year-old patient with a KPS of 80 and a partly resected/IDH1
wild-type/MGMT-methylated tumor has a total prognostic score of 129 and is predicted to have a median survival of approximately 30 months and a
60% probability of surviving two years. This patient is assigned to the low-risk group. (B) Kaplan-Meier estimation of OS and PFS. M: methylated
patients, UM: unmethylated patients, LR: low-risk patients, HR: high-risk patients, mo: month. The difference in survival between groups is reported
(log-rank test p-value). The size and the median survival of each group are also specified.
doi:10.1371/journal.pone.0104455.g001
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intention-to-treat population. However, the interaction between
MGMT and DGKI in a multivariate Cox model including all
significant prognostic factors (age+KPS+surgery+IDH1+MGMT+
DGKI+MGMT:DGKI) was significant (p = 0.0007). This indicat-
ed that the prognostic value of DGKI was to find in the context of
the MGMT methylation status. A nomogram including this
interaction can be found in Figure S3.
In 2008, Gorlia et al. proposed a nomogram for GBM patients
who underwent either a partial or complete resection and were
assigned to temozolomide and radiotherapy in the presence of a
MGMT promoter methylation assessment (population 3 of the
EORTC and NCIC trial 26981-22981/CE.3). Their nomogram
includes MGMT promoter methylation status, Folstein Mini-
Mental State Examination (MMSE) score, and WHO perfor-
mance status [9]. We propose an updated version of this
nomogram that includes not only MGMT promoter methylation
status and Karnofsky performance score but also age, IDH1
mutational status, and extent of surgery. In the EORTC trial,
elderly patients (.70 years) were excluded, and the prognostic
value of IDH1 was not evident when the trial was designed.
Furthermore, the authors discussed the restricted reliability of the
extent of surgery in their study. Age and extent of surgery were
nonetheless identified by Gorlia et al. in the population of GBM
patients who underwent partial or complete resection and were
assigned to temozolomide and radiotherapy without the knowl-
edge of the MGMT promoter methylation status (population 2 of
the EORTC trial). Because it was not routine to collect MMSE
score in the neurosurgical units involved, we were unable to
evaluate the prognostic value of these nomograms on our cohort.
However, the nomogram proposed in the present study showed
better performance evaluation (AUC) than MGMT status alone
(0.71[0.65–0.78] vs. 0.65[0.59–0.71], p,1e-08). The potential
Figure 2. Prognostic value of DGKI methylation status. (A) MGMT-methylated GBM patients assigned to standard treatment (population 2).
Kaplan-Meier estimation of OS in training and validation cohorts. (B) GBM patients assigned to standard treatment (population 1). Kaplan-Meier
estimation of OS and PFS. M: methylated patients, UM: unmethylated patients, LR: low-risk patients, HR: high-risk patients, mo: month. The difference
in survival between groups is reported (log-rank test p-value). The size and the median survival of each group are also specified.
doi:10.1371/journal.pone.0104455.g002
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skewing effect of treatment at recurrence on patient survival was
not controlled; however, the validity of our PFS results indicated
that our findings could be independent of these treatments. A
recent study showed that the nomogram designed by Gorlia et al.
for the intention-to-treat population (radiotherapy only or
temozolomide and radiotherapy) was a poor predictor of an
individual patient’s survival because the standard of care has
evolved since the EORTC trial [17]. Unfortunately, the nomo-
grams proposed by Gorlia et al. for GBM patients who received
the standard treatment (population 2 and population 3 of the
EORTC trial) were not evaluated in the study by Parks et al.
However, our study confirmed the appropriateness of Gorlia et al.
findings as we also identified MGMT methylation status,
performance status, age and extent of surgery in the nomogram
for the population of GBM patients assigned to standard
treatment.
A nomogram-based stratification of our cohort of primary GBM
patients treated with the standard regimen identified two risk
groups (high/low) with significantly different median survival. The
low-risk group was almost exclusively composed of MGMT-
methylated patients. Interestingly, our previous study showed that
the methylation status of the DGKI promoter identified GBM
patients with MGMT-methylated tumors who responded poorly to
the standard regimen [10]. In this study, we have validated the
prognostic value of DGKI methylation status for MGMT-
methylated patients (population 2). However, this finding could
be restricted by the limited size of the training and validation
cohorts. We further evaluated the potential predictive value of
DGKI methylation status on the intention-to-treat population
(population 1). The methylation status of the DGKI promoter
identified 22% of poorly responding patients in the low-risk group
but had no prognostic value for high-risk patients. The role of
DGKI and the functional consequences of its methylation status
have never been investigated in gliomas but DGKI regulates Ras
signalling, an oncogenic pathway frequently altered in GBM
[11,12]. Recently, Revill et al. showed that DGKI was hyper-
methylated in primary hepatocellular carcinoma and was re-
expressed in liver cancer cell lines after exposure to reagents
reversing DNA methylation [18]. This study suggests that DGKI
expression is regulated by its promoter methylation. In GBM, we
observed an anti-correlation between DGKI expression and
methylation levels, in a private cohort and in the TCGA cohort
(data not shown). Further functional studies on DGKI are clearly
required.
Our results improve the conventional MGMT stratification of
GBM patients receiving standard treatment. In particular, the
DGKI methylation status identified poorly responding patients in
the group of low-risk or MGMT-methylated patients. A retro-
spective study precluding the establishment of firm conclusions,
these results need to be validated in a prospectively recruited
cohort. They could however be of help in the interpretation of
published or ongoing clinical trial outcomes and refine patient
recruitment in the future.
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